退市

Search documents
ST新潮:因未披露定期报告 公司股票自2025年5月6日起停牌
news flash· 2025-05-29 11:35
ST新潮(600777)公告,因定期报告涉及的部分财务信息需要进一步补充提供,公司无法在法定期限 内披露2024年年度报告及2025年第一季度报告。公司股票自2025年5月6日起停牌。如公司在股票停牌两 个月内仍未披露2024年年度报告的,则将被实施退市风险警示并复牌。如公司股票交易被实施退市风险 警示之日起的两个月内仍未披露过半数董事保证真实、准确、完整的2024年年度报告,公司股票存在被 上海证券交易所决定终止上市的风险。 ...
靠灯盏花素闻名的龙津药业退市在即
Xin Lang Cai Jing· 2025-05-29 10:59
5月29日,智通财经记者拨打龙津药业投资者电话,对方工作人员称退市后的相关安排已在相关公告中披露。截至5月29日收盘,龙津药业的市值为4.53亿 元。 2024年5月6日,龙津药业因2023年度经审计的净利润为负值且营业收入低于1亿元,被实施退市风险警示。 时隔将近一年,2025年4月25日,龙津药业在股票交易被实施退市风险警示后披露的首个年报显示,2024年度经审计的利润总额、净利润、扣除非经常性损 益后的净利润三者孰低为负值,且扣除后的营业收入低于3亿元。据深交所股票上市规则,龙津药业已触及股票终止上市情形。 2025年6月6日起,龙津药业将进入退市整理期,退市整理期届满的次一交易日,深交所对龙津药业股票予以摘牌,即终止上市。在退市整理期交易期间,龙 津药业将不筹划或实施重大资产重组事项。 龙津药业在今年4月25日发布的《关于退市情况的专项报告》中曾表示,退市整理期间,公司的证券代码不变,股票简称后冠以退标识,退市整理股票进入 风险警示板交易。退市整理期的交易期限为十五个交易日。公司将在股票被终止上市后及时做好相关工作,确保公司股票在摘牌之日起四十五个交易日内可 以进入全国中小企业股份转让系统挂牌转让。 ...
上市即巅峰,连续43个跌停,从106跌到0.06,里面散户全线被套!
Sou Hu Cai Jing· 2025-05-29 01:09
一只股票能跌多狠?你简直都无法想象,这应该是大A最便宜的股票了吧,能从106元跌到6分,对你没看错,就是0.06元,从天堂跌到地狱,不知道有多 少股民上套了? 这只股票发行价75元,上市之后最高涨到106元,然后就是一路下跌,直接跌到退市,退市前来了16个一字跌停,到老三板又来了27个跌停,一共43个跌 停,股价也从最高的106元跌到了0.06元,这哪是割韭菜的,这是来拔韭菜的吧,马上就把韭菜连根拔起了! 这只股票就是搜于特,公司发行价高达75元,发行市盈率113倍,于2010年11月7日在深交所上市。搜于特的主营业务为从事品牌服饰运营,供应链管理等 业务。那时候正赶上品牌服装的热潮,上市后股价一路攀升,最高涨到了106.49元,成为当时股市里为数不多的几只百元股,要知道当时茅台也才100多 元,可见当时也算是一只大牛股了。 当时搜于特的保荐机构是华泰联合证券,当初华泰证券把发行价定在了75元,发行2000万股,募集资金15亿,华泰联合证券拿走了100万的保荐费,而且 搜于特上市以后累计募集了近40亿! 看看搜于特上市之后的表现,真的是上市即巅峰,上市之后最高涨到了106元,然后就是一路下跌,在2015年牛市 ...
宁波波导股份有限公司股票交易异常波动公告
Shang Hai Zheng Quan Bao· 2025-05-28 19:11
Core Viewpoint - The stock of Ningbo Baodao Co., Ltd. has experienced abnormal trading fluctuations, with a cumulative price increase deviation exceeding 12% over three consecutive trading days, leading to a risk warning for potential delisting due to negative net profit and low operating revenue [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price increased by more than 12% cumulatively over three consecutive trading days on May 26, 27, and 28, 2025, which is classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][3]. - The company has confirmed that there are no undisclosed significant events that should have been reported, following inquiries with its controlling shareholder [5]. Group 2: Financial Performance - For the fiscal year 2024, the company's net profit, after excluding non-recurring gains and losses, is negative, and its operating revenue, after excluding unrelated business income, is below 300 million yuan [2][8]. - The company has not yet initiated its share repurchase plan, which was approved in recent board meetings, indicating uncertainty regarding the implementation of this plan [5]. Group 3: Management and Governance - The company's board of directors has confirmed that there are no undisclosed matters that should be reported according to stock listing rules, and previous disclosures do not require correction or supplementation [8]. - During the period of stock price fluctuations, the company's directors, supervisors, senior management, and controlling shareholders did not engage in buying or selling the company's stock [8].
剑指资金占用顽疾 监管层下重手要求上市公司整改
Zheng Quan Ri Bao Zhi Sheng· 2025-05-28 16:39
Core Viewpoint - The regulatory authorities in China are intensifying their scrutiny of the misuse of funds by listed companies, particularly focusing on the actions of major shareholders and actual controllers who exploit company resources for personal gain [1][2][3]. Regulatory Actions - The China Securities Regulatory Commission (CSRC) has introduced new rules requiring listed companies to promptly demand the return of misappropriated funds and disclose the reasons for such actions, their impact on the company, and the rectification plans [1][2]. - As of May 28, 2023, there have been 48 administrative measures or penalties against 37 companies related to fund misuse, including warnings, fines, and orders for correction [1][2]. Enforcement Against Major Shareholders - The regulatory bodies are targeting the "key minority," which includes major shareholders and executives who engage in fund misappropriation, with a focus on both direct and indirect methods of fund occupation [2][3]. - Specific cases, such as the reprimand of ST Dongshi for failing to return 106 million yuan of raised funds, illustrate the ongoing enforcement actions against individuals involved in fund misuse [2][3]. Accountability Mechanisms - The regulatory framework emphasizes that misappropriated funds must be returned, with strict deadlines for rectification and potential delisting for non-compliance [4][5]. - Companies are encouraged to utilize legal measures, such as lawsuits and asset freezes, to recover misappropriated funds, ensuring the protection of minority shareholders [5][6]. Independent Oversight - Independent directors are actively involved in urging management to recover misappropriated funds, as seen in the case of ST Changkang, where independent directors issued a reminder to address fund occupation issues [6]. - The China Securities Investor Services Center is promoting collective and derivative lawsuits to enhance investor protection and ensure accountability for fund misuse [6].
300108 明日摘牌
Zhong Guo Zheng Quan Bao· 2025-05-28 15:17
Core Viewpoint - *ST Jiyuan's stock has been terminated from listing due to continuous trading below 1 yuan for 20 consecutive trading days, leading to a significant decline in its market value and operational challenges [2][3][4]. Group 1: Stock Termination and Transition - The Shenzhen Stock Exchange has decided to terminate the listing of *ST Jiyuan's stock, effective May 29, following a period of poor stock performance [2]. - The company is required to ensure that its shares can enter the National Small and Medium Enterprises Share Transfer System within 45 trading days after delisting [2]. - *ST Jiyuan has appointed Shanxi Securities Co., Ltd. as its main broker to assist with the share transfer process and related matters [2]. Group 2: Financial Performance and Challenges - *ST Jiyuan has experienced a cumulative stock price decline of 83.59% since the beginning of the year, reflecting severe financial distress [3]. - The company reported a revenue of 333 million yuan for 2024, a year-on-year decrease of 3.69%, and a net loss of 439 million yuan, indicating an increase in the loss margin compared to the previous year [4]. - The company faces significant operational challenges due to severe liquidity shortages, overdue debts, and multiple lawsuits, which have led to the freezing of bank accounts and assets [4][5]. Group 3: Audit and Bankruptcy Proceedings - The financial report for 2024 received an audit opinion of "unable to express" from Beijing Dehao International Accounting Firm, highlighting major uncertainties regarding the company's ability to continue operations [5]. - In 2023, *ST Jiyuan applied for bankruptcy reorganization due to its inability to repay debts and lack of repayment capacity, but the pre-reorganization process was ultimately unsuccessful [7]. - The court determined that the pre-reorganization plan was not approved, increasing the risk of delisting for the company [7].
它今天退市!今年第12家!
IPO日报· 2025-05-28 13:27
星标 ★ IPO日报 精彩文章第一时间推送 5月28日晚间,吉药控股集团股份有限公司(300108.SZ,下称"*ST吉药")发布公告称,公司股 票已被深圳证券交易所决定终止上市,将在2025年5月29日被摘牌。公司股票因触及交易类强制退 市情形被本所作出终止上市决定,不进入退市整理期。 AI制图 回顾公司退市流程,4月23日晚间,公司披露称, 截至2025年4月23日,公司因股票连续20个交 易日收盘价低于1元,触发深交所终止上市规则,公司股票将被终止上市。公司股票将于4月24日 开市起停牌。 5月26日,公司收到深交所《关于吉药控股集团股份有限公司股票终止上市的决定》,深交所决定 终止公司股票上市。 据悉,公司前身为通化双龙化工股份有限公司,主营国防化工用白炭黑生产。2014年通过收购金 宝药业转型医药领域,形成"化工+医药"双主业模式。 2017年更名为吉药控股后,公司便开启了激进并购的模式,三年内收购普华制药、亚利大胶丸等 十余家企业,业务覆盖医药工业、商业、研发等八大板块。 记者 吴鸣洲 文字编辑 褚念颖 版面编辑 光云 更多精彩 然而,不断的跨界扩张带来了大额的商誉风险, 2019年至2024年, ...
退市!又一A股公司摘牌,涉近3万股东
证券时报· 2025-05-28 11:45
*ST吉药将在29日被摘牌,不进入退市整理期。 *ST吉药(300108)5月28日晚间公告称,公司股票已被深圳证券交易所决定终止上市,将在2025年5月29日被摘牌。公司股票因触及交易类强制退 市情形被深圳证券交易所作出终止上市决定,不进入退市整理期。 根据公告,*ST吉药于2025年5月26日收到深圳证券交易所《关于吉药控股集团股份有限公司股票终止上市的决定》(深证上〔2025〕第517 号),鉴于公司股票被深圳证券交易所决定终止上市,根据《深圳证券交易所创业板股票上市规则(2024年修订)》《关于退市公司进入退市 板块挂牌转让的实施办法》等的相关规定,公司应当在股票被终止上市后及时做好相关工作,以确保公司股份在摘牌后四十五个交易日内可以 进入全国中小企业股份转让系统有限责任公司依托原证券公司代办股份转让系统设立并代为管理的两网公司及退市公司板块(以下简称"退市板 块")挂牌转让。 据了解,公司已聘请山西证券股份有限公司担任公司主办券商,并与其在2025年5月27日签订了《委托股票转让协议》,委托其为公司提供股份 转让服务,办理交易所市场的股份退出登记、股份重新确认、退市板块的股份初始登记、股票挂牌及提供 ...
*ST苏吴: 江苏吴中医药发展股份有限公司关于立案调查进展暨风险提示公告
Zheng Quan Zhi Xing· 2025-05-28 11:03
证券代码:600200 证券简称:*ST 苏吴 公告编号:临 2025-046 江苏吴中医药发展股份有限公司 关于立案调查进展暨风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实、准确和完整承担法律责任。 重要风险提示: 公司于 2025 年 2 月 27 日披露了《江苏吴中医药发展股份有限公司关于收到 中国证券监督管理委员会立案告知书暨风险提示公告》 因公司涉嫌信息披露违法违规,根据《中华人民共和国证券法》《中华人民共和 国行政处罚法》等法律法规,中国证监会决定对公司立案。 截至本公告披露日,中国证监会的调查尚在进行中,公司尚未收到就上述立 案调查事项的结论性意见或决定。在立案调查期间,公司积极配合中国证监会的 相关调查工作。 若后续经中国证监会行政处罚认定的事实,触及《上海证券交易所股票上市 规则》规定的重大违法强制退市情形,公司股票将被实施重大违法强制退市。请 投资者理性投资,注意投资风险。 公司目前日常生产经营正常,市场环境或行业政策未发生其他重大变化。公 司郑重提醒广大投资者,公司指定信息披露媒体为《中国证券报》《上海证券报》 及上海证券 ...
*ST万方(000638) - 000638*ST万方投资者关系管理信息20250527
2025-05-27 11:26
证券代码:000638 证券简称:*ST 万方 万方城镇投资发展股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研□分析师会议 | | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | □新闻发布会□路演活动 | | | □现场参观 | | | □其他(请文字说明其他活动内容) | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2025 年 5 月 27 日 (周二) 下午 15:00~16:30 | | 地点 | 公司通过全景网"投资者关系互动平台"(https://ir.p5w.net) | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长、总经理刘玉女士 | | 员姓名 | 2、副董事长、副总经理、董事会秘书郭子斌女士 | | | 3、副总经理董威亚先生 | | | 4、财务总监谌志旺先生 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复: | | | 1、请问公司目前虾青素基地一期工程修好了没? | | | 您好,感谢您的提问,目前公司的 ...